Regulatory approvals, trial data, and major licensing deals in 2026 are accelerating subcutaneous biologics, cutting patient burden and reshaping biopharma strategy.
|Articles|February 28, 2022
Johnson & Johnson Confirm Advancement of Nationwide Opioid Settlement Agreement
Author(s)BioPharm International Editors
Johnson & Johnson has confirmed advancement of the nationwide opioid settlement agreement.
Advertisement
Johnson & Johnson and Janssen Pharmaceutical Companies confirmed on Feb. 25, 2022 that there is sufficient participation to advance the nationwide opioid settlement agreement to resolve opioid-related claims and litigation by states, cities, counties, and other subdivisions in the United States.
The settlement is designed to directly support state and local efforts to address the opioid crisis in the US. Johnson & Johnson will contribute up to $5 billion to the settlement. The company also no longer sells prescription opioid medications in the US as part of the efforts. According to the company, the settlement agreement is not an admission of any liability or wrongdoing, and the company will continue to defend any litigation that this final settlement agreement does not resolve.
Separate settlement agreements were made between the company and the states of New York, Texas, Nevada, and New Mexico that are consistent with the nationwide settlement agreement. The company also announced a settlement agreement with the federally recognized Tribes. The dollar amounts to be received in these settlement agreements will be deducted from the $5 billion nationwide settlement agreement amount in the form of pro rata shares.
Source:
Advertisement
Related to this article
Tambotatug pelitecan (Tam-Peli), a B7-H3-targeted antibody-drug conjugate, is the second of at least three B7-H3-targeted ADCs to post positive late-stage data in relapsed small-cell lung cancer this year.
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
Samsung Biologics signed a $262 million contract manufacturing agreement with an undisclosed European pharmaceutical company, extending production commitments through 2033 and lifting the CDMO's cumulative contract value past $21.9 billion.
CordenPharma is expanding its Caponago, Italy site with a €80 million multi-year investment and new aseptic fill-finish lines, aiming to reach 500 million sterile injectable units of annual capacity to meet rising demand across peptide, biologic, LNP, and oligonucleotide-based drug products.
Solstice Oncology launched with a $225 million Series A financing to advance porustobart, a second-generation, Fc-enhanced CTLA-4 antibody licensed from Harbour BioMed, into neoadjuvant Phase 2 testing for microsatellite-stable colon cancer.
Encoded Therapeutics closed a $275 million Series F financing to fund pivotal and expansion studies of ETX101, an AAV9-mediated gene regulation therapy for SCN1A-positive Dravet syndrome, alongside commercial-scale buildout of the company's in-house GMP manufacturing.
Amgen and AstraZeneca announced that the Phase 3 DeLLphi-305 trial met its primary endpoint, with Imdelltra (tarlatamab) plus Imfinzi (durvalumab) significantly improving overall survival versus durvalumab alone as first-line maintenance therapy for extensive-stage small cell lung cancer — the first phase 3 study of a bispecific T-cell engager to show a survival benefit in this earlier-line setting.
Advertisement
Advertisement